Wie hoch ist der Preis für Marinus Pharmaceuticals, Inc. (MRNS)

Preis für Marinus Pharmaceuticals, Inc. (MRNS) ist $0.55

Wie hoch ist die Marktkapitalisierung für Marinus Pharmaceuticals, Inc. (MRNS)

Marktkapitalisierung für Marinus Pharmaceuticals, Inc. (MRNS) ist $28.90M

Marinus Pharmaceuticals, Inc. (MRNS) Gewinne

Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.

Jahr	Gewinn	ändert
2026 (TTM)	$-140.49M	-1.72%
2023	$-142.94M	770.17%
2022	$-16.43M	-83.37%
2021	$-98.78M	46.39%
2020	$-67.48M	24.67%
2019	$-54.12M	47.36%
2018	$-36.73M	94.34%
2017	$-18.90M	-34.02%
2016	$-28.64M	15.26%
2015	$-24.85M	129.39%
2014	$-10.83M	105.57%
2013	$-5.27M	274.13%
2012	$-1.41M	0.00%

Jahr

Gewinn

ändert

2026 (TTM)

$-140.49M

-1.72%

2023

$-142.94M

770.17%

2022

$-16.43M

-83.37%

2021

$-98.78M

46.39%

2020

$-67.48M

24.67%

2019

$-54.12M

47.36%

2018

$-36.73M

94.34%

2017

$-18.90M

-34.02%

2016

$-28.64M

15.26%

2015

$-24.85M

129.39%

2014

$-10.83M

105.57%

2013

$-5.27M

274.13%

2012

$-1.41M

0.00%

Unternehmen	Gewinn	Gewinnunterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-3,854.62%	US
Moderna, Inc. MRNA.US	$-3.09B	2,097.29%	US
Argenx SE ARGX.US	$1.95B	-1,488.45%	NL
CSL Limited CSL.AX	$1.61B	-1,249.03%	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

Gewinn

Gewinnunterschied

Land